JP2008533986A - 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用 - Google Patents

変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用 Download PDF

Info

Publication number
JP2008533986A
JP2008533986A JP2008502560A JP2008502560A JP2008533986A JP 2008533986 A JP2008533986 A JP 2008533986A JP 2008502560 A JP2008502560 A JP 2008502560A JP 2008502560 A JP2008502560 A JP 2008502560A JP 2008533986 A JP2008533986 A JP 2008533986A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
isolated
antibody
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008502560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008533986A5 (https=
Inventor
ベカ ソロモン，
サラ オーガド，
イタイ ベンハー，
ロニト ロゼンフェルド，
Original Assignee
ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド filed Critical ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド
Publication of JP2008533986A publication Critical patent/JP2008533986A/ja
Publication of JP2008533986A5 publication Critical patent/JP2008533986A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008502560A 2005-03-25 2006-03-23 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用 Pending JP2008533986A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66496705P 2005-03-25 2005-03-25
US69891905P 2005-07-14 2005-07-14
PCT/IL2006/000372 WO2006100681A2 (en) 2005-03-25 2006-03-23 Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Publications (2)

Publication Number Publication Date
JP2008533986A true JP2008533986A (ja) 2008-08-28
JP2008533986A5 JP2008533986A5 (https=) 2009-03-12

Family

ID=36617330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008502560A Pending JP2008533986A (ja) 2005-03-25 2006-03-23 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用

Country Status (6)

Country Link
US (2) US8039594B2 (https=)
EP (1) EP1863846B1 (https=)
JP (1) JP2008533986A (https=)
AT (1) ATE437185T1 (https=)
DE (1) DE602006007967D1 (https=)
WO (1) WO2006100681A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513135A (ja) * 2015-03-23 2018-05-24 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JPWO2018092725A1 (ja) * 2016-11-15 2019-10-17 学校法人東京理科大学 ｐ５３分解誘導分子及び医薬組成物
JP2019535241A (ja) * 2016-10-17 2019-12-12 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｐ５３抗体
US10976306B2 (en) 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1863846B1 (en) 2005-03-25 2009-07-22 Ramot at Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
EP2054515B1 (en) * 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2573565A1 (en) 2011-09-23 2013-03-27 Gerhard Matthias Kresbach Immune detection method for common epitopes of two or more analytes in samples of complex compositions, device, and kit for enabling said immune detection method
EP4412650A1 (en) * 2021-10-05 2024-08-14 The Penn State Research Foundation Methods for treating cancers with mutated p53
CN119866341A (zh) * 2022-07-10 2025-04-22 爱莫布瑞斯疗法公司 重组抗体产生的无细胞方法
CN115876993B (zh) * 2022-11-17 2024-10-15 沈阳农业大学 基于生物膜干涉技术检测病原生物凝集素与唾液酸乳糖亲和力方法的建立

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502553A (ja) * 1996-10-29 2001-02-27 ローヌ―プーラン・ロレ・エス・アー 抗ｐ５３一本鎖抗体フラグメント及びその使用
WO2001068801A2 (en) * 2000-03-16 2001-09-20 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1863846B1 (en) 2005-03-25 2009-07-22 Ramot at Tel-Aviv University Ltd. Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502553A (ja) * 1996-10-29 2001-02-27 ローヌ―プーラン・ロレ・エス・アー 抗ｐ５３一本鎖抗体フラグメント及びその使用
WO2001068801A2 (en) * 2000-03-16 2001-09-20 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513135A (ja) * 2015-03-23 2018-05-24 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JP2021121190A (ja) * 2015-03-23 2021-08-26 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JP2023085528A (ja) * 2015-03-23 2023-06-20 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
JP7304911B2 (ja) 2015-03-23 2023-07-07 ザ ジョンズ ホプキンス ユニバーシティー 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ
US10976306B2 (en) 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
JP2019535241A (ja) * 2016-10-17 2019-12-12 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｐ５３抗体
JP7173964B2 (ja) 2016-10-17 2022-11-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｐ５３抗体
JPWO2018092725A1 (ja) * 2016-11-15 2019-10-17 学校法人東京理科大学 ｐ５３分解誘導分子及び医薬組成物
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
JP7061801B2 (ja) 2016-11-15 2022-05-02 学校法人東京理科大学 ｐ５３分解誘導分子及び医薬組成物
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using

Also Published As

Publication number Publication date
ATE437185T1 (de) 2009-08-15
DE602006007967D1 (de) 2009-09-03
EP1863846A2 (en) 2007-12-12
US8207309B2 (en) 2012-06-26
US8039594B2 (en) 2011-10-18
EP1863846B1 (en) 2009-07-22
WO2006100681A2 (en) 2006-09-28
US20100074908A1 (en) 2010-03-25
WO2006100681A3 (en) 2007-05-24
US20110262447A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
JP7393447B2 (ja) Ｆｒｉｚｚｌｅｄタンパク質に対する抗体及びその使用方法
US11242405B2 (en) Monoclonal antigen-binding proteins to intracellular oncogene products
KR101602870B1 (ko) 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US8207309B2 (en) Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses
JP6709212B2 (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
KR101602876B1 (ko) 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
JP7452829B2 (ja) アミロイドベータのエピトープおよびそれに対する抗体
CN112334484A (zh) 抗-CD3ε抗体及其应用方法
CN108350052A (zh) 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
RU2534890C2 (ru) Антитела против mst1r и их применение
KR102527315B1 (ko) 항-Ang2 항체 및 이의 용도
CN113993897A (zh) 抗tie2抗体及其用途
US20240383989A1 (en) Modified anti-vegfr2 (kdr) antibody and use thereof
CN101228187A (zh) 针对突变p53的共同表位的人合成单链抗体及其用途
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
KR101996627B1 (ko) Vcam-1-d6에 결합하는 항체 및 그 용도
HK40062907A (en) Binding proteins specific for lox1 and uses thereof
Martinelli Selection of epitope directed recombinant antibodies to inhibit mutated nucleophosmin activities
HK1255576A1 (en) Binding proteins specific for lox1 and uses thereof
HK1255576B (en) Binding proteins specific for lox1 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120131